{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-405776","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-09-29T01:39:22+00:00","discovered_at":"2026-09-29T10:10:00.125793+00:00","generated_at":"2026-10-12T13:40:23.533936+00:00","sec_items":["1.01","5.03","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"confidence":"high","headline":"AstraZeneca to invest $2B in Summit at $18.36/share, a 10% premium, plus clinical collaboration","bullets":["AstraZeneca Holdings B.V. buys 108,955.3686 Class A Convertible Preferred shares at $18,356.14 each for $2.0B; each converts into 1,000 common shares.","Effective common price of $18.36 equals VWAP of the five trading days from the prior week plus 10%, a premium to Summit's closing price; closing expected by end of this week.","Conversion is blocked until the HSR waiting period ends and a charter amendment authorizing enough common shares is effective; Summit must redeem for cash if the amendment misses an 18-month deadline.","Summit also signed a clinical collaboration with AstraZeneca to test sonesitatug vedotin (sone-ve) plus ivonescimab in gastrointestinal cancers, AstraZeneca-sponsored with shared costs.","A non-binding MOU covers combining ivonescimab with AstraZeneca's ADC portfolio; no milestones, royalties, revenue-sharing or profit-sharing; resale registration due within 60 days of closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-405776","json":"https://secwatch.observer/filing/0001193125-26-405776.json","markdown":"https://secwatch.observer/filing/0001193125-26-405776.md","text":"https://secwatch.observer/filing/0001193125-26-405776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/0001193125-26-405776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000119312526405776/d178892d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:40:23.533936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}